NCT00453895View on ClinicalTrials.gov

Sunitinib in Refractory Adrenocortical Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

July 31, 2007

Primary Completion Date

August 31, 2011

Study Completion Date

February 29, 2012

Conditions
Adrenocortical Carcinoma
Interventions
DRUG

Sunitinib

50mg Sunitinib

Trial Locations (2)

97080

Dept. of Medicine I, University of Wuerzburg, Würzburg

Unknown

Charite Berlin, Berlin

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

University of Wuerzburg

OTHER

NCT00453895 - Sunitinib in Refractory Adrenocortical Carcinoma | Biotech Hunter | Biotech Hunter